Pfizer Increases Prices on Over 60 Drugs, Including Paxlovid
Pfizer has announced price hikes on more than 60 drugs, with a notable 3% increase on its antiviral treatment, Paxlovid. Explore the full details here.
Topic
pharmaceuticals
A collection of 34 issues
Pfizer Opts Out of New Hemophilia A Gene Therapy
Pfizer pulls back on developing a new gene therapy for hemophilia A, citing limited market interest. Explore the implications for the hemophilia community and biotech sector.
Pfizer Alters Timeline for Drug Approval Plans
Pfizer changes plans for US and European drug approval, initially set for early 2025. Explore the implications of this strategic shift.
Roche Maintains Steady R&D Budget
Roche's research and development budget remains unchanged, signaling a stable commitment to innovation. Explore the implications for the pharmaceutical giant's future.
FDA Approves Injectable Version of Opdivo by Bristol Myers Squibb
FDA greenlights injectable Opdivo, enhancing cancer treatment options. Bristol Myers Squibb's PD-1 inhibitor Opdivo gains approval, marking a healthcare innovation.
Revolutionizing Drug Delivery in Healthcare
Discover the emerging trend in healthcare innovation with more convenient drug delivery options revolutionizing the pharmaceuticals industry.
Bristol Myers Squibb Gains FDA Nod for Injectable Opdivo
Bristol Myers Squibb secures FDA approval for injectable Opdivo, potentially reshaping the healthcare sector. Discover its impact on pharmaceuticals.
Gilenya Sales Plummet from $3.22B to $925M in Four Years
Gilenya faces a steep sales decline in the pharmaceutical market, dropping from $3.22 billion in 2019 to $925 million in 2023 due to increased competition.
Court Revives Whistleblower Suit Against Novartis Over Gilenya Kickbacks
U.S. appeals court reinstates lawsuit accusing Novartis of illegal kickbacks to boost sales of its MS drug Gilenya. Explore legal, pharmaceutical, and healthcare implications.
Novartis Hit with Whistleblower Lawsuit Over Gilenya Kickbacks
Novartis is facing legal scrutiny as a whistleblower lawsuit alleges the company paid kickbacks to promote its MS drug Gilenya, impacting the healthcare sector.